Loncar Cancer Immunotherapy ETF (CNCR) Surpasses $50 Million in Assets Under Management

The Loncar Cancer Immunotherapy ETF (Nasdaq: CNCR) recently surpassed $50 million in assets under management (AUM), marking a pivotal milestone for the fund. Launched with a modest seed investment of $2.5 million on Oct. 13, 2015, the ETF has been offering exposure to public companies at the forefront of cancer immunotherapy research for more than two years.